Prothena Corporation PLC (NASDAQ:PRTA)

37.35
Delayed Data
As of Apr 24
 -0.48 / -1.27%
Today’s Change
16.71
Today|||52-Week Range
45.00
+79.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Prothena Corp. Plc is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion. It focuses on therapeutic monoclonal antibodies directed specifically to disease causing proteins. The company's antibody-based product candidates target a number of potential indications including AL and AA forms of amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002) and novel cell adhesion targets involved in inflammatory diseases and cancers (PRX003). Prothena was founded on September 26, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Prothena Corp. Plc
Alexandra House
Dublin Dublin 4
P:(531) 902-3519
Investor Relations:
(650) 837-8535

Employees

Shareholders

Mutual fund holders68.95%
Other institutional26.97%
Individual stakeholders11.70%

Top Executives

Dale B. SchenkPresident, Chief Executive Officer & Director
Tran B. NguyenChief Financial Officer & Head-Investor Relations
Gene G. KinneyChief Scientific Officer
Martin KollerChief Medical Officer
Karin L. WalkerChief Accounting Officer & Controller

To view my watchlist

Not a member yet?

Sign up now for a free account